A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague

Vaccine

Volumn 22, Issue 25-26, 2004, Pages 3348-3357

  Wang, Shixia ^a   Heilman, Destin ^a   Liu, Fangjun ^a   Giehl, Theodore ^a   Joshi, Swati ^a   Huang, Xiaoyun ^a   Chou, Te Hui ^a   Goguen, Jon ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

DNA vaccine; LcrV antigen; tPA leader; Yersinia pestis

Indexed keywords

ANTIBODY; ANTIGEN; DNA VACCINE; IMMUNOGLOBULIN G2A; OLIGOMER; TISSUE PLASMINOGEN ACTIVATOR;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; LETHALITY; MOUSE; NONHUMAN; NOSE MUCOSA; PLAGUE; PRIORITY JOURNAL; PROVOCATION TEST; SIGNAL TRANSDUCTION; VACCINATION; YERSINIA PESTIS;

ANIMALS; ANTIGENS, BACTERIAL; BLOTTING, WESTERN; CHEMISTRY, PHARMACEUTICAL; COLONY COUNT, MICROBIAL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PLAGUE; PLAGUE VACCINE; PLASMIDS; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE PLASMINOGEN ACTIVATOR; VACCINES, DNA; YERSINIA PESTIS;

EID: 4043113524     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.02.036     Document Type: Article

References (42)

1. http://www.csl.com.au/.
2. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., Titball R.W. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine. 15(10):1997;1079-1084
3. Williamson E.D., Eley S.M., Stagg A.J., Green M., Russell P., Titball R.W. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine. 19(4-5):2001;566-571
4. Perry R.D., Fetherston J.D. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10(1):1997;35-66
5. Rodrigues C.G., Carneiro C.M., Barbosa C.T., Nogueira R.A. Antigen F1 from Yersinia pestis forms aqueous channels in lipid bilayer membranes. Braz. J. Med. Biol. Res. 25(1):1992;75-79
6. Williams R.C. Jr., Gewurz H., Quie P.G. Effects of fraction I from Yersinia pestis on phagocytosis in vitro. J. Infect. Dis. 126(3):1972;235-241
7. Andrews G.P., Heath D.G., Anderson G.W. Jr., Welkos S.L., Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun. 64(6):1996;2180-2187
8. Williamson E.D., Eley S.M., Griffin K.F., et al. A new improved sub-unit vaccine for plague: the basis of protection, FEMS Immunol. Med. Microbiol. 12(3-4):1995;223-230
9. Titball R.W., Howells A.M., Oyston P.C., Williamson E.D. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect. Immun. 65(5):1997;1926-1930
10. Pettersson J., Holmstrom A., Hill J., et al. The V-antigen of Yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol. 32(5):1999;961-976
11. 2+ response, and virulence of Yersinia pestis. J. Bacteriol. 177(9):1995;2530-2542
12. Fields K.A., Straley S.C. LcrV of Yersinia pestis enters infected eukaryotic cells by a virulence plasmid-independent mechanism. Infect Immun. 67(9):1999;4801-4813
13. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect. Immun. 63(8):1995;2854-2858
14. Sodeinde O.A., Subrahmanyam Y.V., Stark K., Quan T., Bao Y., Goguen J.D. A surface protease and the invasive character of plague. Science. 258(5084):1992;1004-1007
15. MacGregor R.R., Boyer J.D., Ciccarelli R.B., Ginsberg R.S., Weiner D.B. Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data. J. Infect. Dis. 181(1):2000;406
16. Roy M.J., Wu M.S., Barr L.J., et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine. 19(7-8):2000;764-778
17. Ugen K.E., Nyland S.B., Boyer J.D., et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine. 16(19):1998;1818-1821
18. Wang R., Doolan D.L., Le T.P., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science. 282(5388):1998;476-480
19. McConkey S.J., Reece W.H., Moorthy V.S., et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6):2003;729-735
20. Riemenschneider J., Garrison A., Geisbert J. Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. Vaccine. 21(25-26):2003;4071-4080
21. Bennett A.M., Phillpotts R.J., Perkins S.D., Jacobs S.C., Williamson E.D. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersinia pestis or Venezuelan Equine Encephalitis virus. Vaccine. 18(7-8):2000;588-596
22. Williamson E.D., Bennett A.M., Perkins S.D., Beedham R.J., Miller J., Baillie L.W. Co-immunisation with a plasmid DNA cocktail primes mice against anthrax and plague. Vaccine. 20(23-24):2002;2933-2941
23. Lu S., Arthos J., Montefiori D.C., et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70(6):1996;3978-3991
24. Lu S., Santoro J.C., Fuller D.H., Haynes J.R., Robinson H.L. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology. 209(1):1995;147-154
25. Lu S., Wyatt R., Richmond J.F., et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses. 14(2):1998;151-155
26. Robinson H.L., Boyle C.A., Feltquate D.M., Morin M.J., Santoro J.C., Webster R.G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J. Infect. Dis. 176(Suppl 1):1997;S50-S55
27. Lu S, Manning S, Arthos J. Antigen engineering in DNA immunization. In: Lowrie DB, Whalen RG, edotors. Methods in molecular medicine, vol. 29. Totowa, NJ: Human Press Inc.; 1998. p. 355-74.
28. Hu P., Elliott J., McCready P., et al. Structural organization of virulence-associated plasmids of Yersinia pestis. J Bacteriol. 180(19):1998;5192-5202
29. Wang S., Joshi S., Lu S. Delivery of DNA to skin by particle bombardment. Methods Mol Biol. 245:2004;185-196
30. Tito M.A., Miller J., Walker N., et al. Probing molecular interactions in intact antibody: antigen complexes, an electrospray time-of-flight mass spectrometry approach. Biophys. J. 81(6):2001;3503-3509
31. Feltquate D.M., Heaney S., Webster R.G., Robinson H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 158(5):1997;2278-2284
32. Grosfeld H., Chohen S., Bino T., et al. Effective protective immunity to Yrsinia pestis infection conferred by DNA vaccine coding for derivatives of the F1 capsular antigen. Infect. Immun. 71(1):2003;374-383
33. Ulmer J.B., Donnelly J.J., Parker S.E., et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259(5102):1993;1745-1749
34. Robinson H.L., Montefiori D.C., Johnson R.P., et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5(5):1999;526-534
35. Heath D.G., Anderson G.W. Jr., Mauro J.M. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine. 16(11-12):1998;1131-1137
36. Hill J., Leary S.E., Griffin K.F., Williamson E.D., Titball R.W. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization. Infect. Immun. 65(11):1997;4476-4482
37. Li Y., Luo L., Thomas D.Y., Kang C.Y. The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding. Virology. 272(2):2000;417-428
38. Sing A., Roggenkamp A., Geiger A.M., Heesemann J. Yersinia enterocolitica evasion of the host innate immune response by V antigen-induced IL-10 production of macrophages is abrogated in IL-10-deficient mice. J. Immunol. 168(3):2002;1315-1321
39. Eyles J.E., Williamson E.D., Spiers I.D., Alpar H.O. Protection studies following bronchopulmonary and intramuscular immunisation with yersinia pestis F1 and V subunit vaccines coencapsulated in biodegradable microspheres: a comparison of efficacy. Vaccine. 18(28):2000;3266-3271
40. Alpar H.O., Eyles J.E., Williamson E.D., Somavarapu S. Intranasal vaccination against plague, tetanus and diphtheria. Adv. Drug. Deliv. Rev. 51(1-3):2001;173-201
41. Williamson ED. The F1 + V combined sub-unit vaccine. In: NIH Plague Vaccine Meeting, Bethesda, MD, USA, 2002.
42. Adamovicz, J. Efficacy of the F1-V fusion protein vaccine in non-human primates. In: NIH Plague Vaccine Meeting 2002, Bethesda, MD, USA, November 22, 2002.